3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
5
Head & Neck
2
CNS
2
Sarcoma
1
NET
1
Lymphoid
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
Breast
1
Conditions
Thyroid Neoplasms
1
Thyroid Cancer, Papillary
1
Thoracic Neoplasms
1
Sarcoma
1
Salivary Gland Neoplasms
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms by Site
1
Neoplasms
1
Melanoma
1
Lymphoma, Large-Cell, Anaplastic
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Gastrointestinal Diseases
1
Digestive System Neoplasms
1
Digestive System Diseases
1
Colorectal Neoplasms
1
Colonic Diseases
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Bronchogenic
1
Bronchial Neoplasms
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Everolimus
10
lanreotide
4
Capecitabine
4
pasireotide
3
lutetium Lu 177 dotatate
3
lenvatinib
3
fosbretabulin
3
Temozolomide
3
Sorafenib
3
Paclitaxel
3
Octreotide
3
Nivolumab
3
Magnetic Resonance Spectroscopy
3
Filgrastim
3
Erlotinib Hydrochloride
3
Doxorubicin
3
trifluridine tipiracil drug combination
2
surufatinib
2
pembrolizumab
2
pegfilgrastim
2
gallium Ga 68 dotatate
2
durvalumab
2
dactolisib
2
Surveys and Questionnaires
2
Surgical Procedures, Operative
2
Sunitinib
2
Rosiglitazone
2
Radiotherapy
2
Panobinostat
2
Mitotane
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
alectinib
×
Endocrine
×
Clear all
NCT04644315
2023-08-07
ALpha-T
Hoffmann-La Roche
Phase 2
Terminated
1 enrolled
5 charts